WEBINAR: Normalization of organ-on-a-chip samples for mass spectrometry based proteomics and metabolomics via dansylation-based assay – 28 June 2023

cnb825 webinar promo v1 |
Learn more
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • Immune-mediated DILI – Predicting the unpredictable!

      • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

      • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System  

      View all news

      Upcoming Events

      • ISSX DMDG 2023

      • MPS World Summit Berlin 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

The PNPLA3 I148 variant enhances the disease phenotype of hepatic stellate cells in an in vitro model of non-alcoholic fatty liver disease

August 11, 2018 by

Resource > Posters >

The PNPLA3 I148 variant enhances the disease phenotype of hepatic stellate cells in an in vitro model of non-alcoholic fatty liver disease


American Association for the Study of Liver Diseases (AASLD)

Filed under: Disease modeling and NAFLD/NASH

The PNPLA3 1148 variant enhances the disease EDIT |
Access resource

Kostrzewski et al

Non-Alcoholic Fatty Liver Disease (NAFLD) is now considered the most predominant cause of chronic liver disease in the Western world and its worldwide prevalence continues to increase. NAFLD includes a wide spectrum of liver abnormalities with the most severe cases involving progressive liver injury in the form of Non-Alcoholic Steatohepatitis (NASH). Key characteristics of NASH include lipid accumulation in hepatocytes, chronic inflammation, collagen deposition, and fibrosis. There are currently no FDA-approved drugs for the treatment of NAFLD/NASH and there is a clear requirement for better models to understand this disease. ​

The single nucleotide polymorphism I148M in the gene encoding patatin-like phospholipase domain-containing protein 3 (PNPLA3) is strongly associated with adverse outcomes for NAFLD patients. PNPLA3 I148M is associated with increased hepatic inflammation, steatosis, and enhanced development and severity of liver fibrosis. The mutation is proposed to directly affect primary human hepatocyte (PHH) propensity to become steatotic and the fibrogenic phenotype of hepatic stellate cells (HSC). Primary I148M HSC have been shown to demonstrably produce more inflammatory mediators, and have higher lipid droplet content than equivalent wild-type (WT) HSC. PNPLA3 I148M effects in HSC have only been explored in isolation and not in a NAFLD disease model. Using a fully human in vitro NAFLD triple co-culture model, which comprises PHH, Kupffer (HK), and HSC, we investigated how PNPLA3 I148M in HSC influenced NAFLD development.

Access resource

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility | Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023
  • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System   February 27, 2023

Upcoming events

ISSX DMDG 2023 June 11-14, 2023

MPS World Summit Berlin 2023 June 26-30, 2023